share_log

Analysts Expect Breakeven For Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Before Long

Analysts Expect Breakeven For Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Before Long

分析師預計,不久之後,Iovance Biotherapeutics, Inc.(納斯達克股票代碼:IOVA)將實現盈虧平衡
Simply Wall St ·  05/22 00:14

We feel now is a pretty good time to analyse Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) business as it appears the company may be on the cusp of a considerable accomplishment. Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. With the latest financial year loss of US$444m and a trailing-twelve-month loss of US$450m, the US$2.9b market-cap company amplified its loss by moving further away from its breakeven target. Many investors are wondering about the rate at which Iovance Biotherapeutics will turn a profit, with the big question being "when will the company breakeven?" We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

我們認爲現在是分析Iovance Biotherapeutics, Inc.的好時機。”s(納斯達克股票代碼:IOVA)的業務看來該公司可能正處於取得重大成就的風口浪尖。Iovance Biotherapeutics, Inc. 是一家處於商業階段的生物技術公司,在美國開發和商業化使用自體腫瘤浸潤淋巴細胞治療轉移性黑色素瘤和其他實體瘤癌的細胞療法。這家市值29億美元的公司最近一個財年的虧損爲4.44億美元,過去十二個月的虧損爲4.5億美元,進一步偏離盈虧平衡目標,從而擴大了虧損。許多投資者想知道Iovance Biotherapeutics的盈利速度,最大的問題是 “公司何時會實現盈虧平衡?”我們簡要概述了行業分析師對該公司、盈虧平衡年份和隱含增長率的預期。

Consensus from 12 of the American Biotechs analysts is that Iovance Biotherapeutics is on the verge of breakeven. They expect the company to post a final loss in 2025, before turning a profit of US$11m in 2026. So, the company is predicted to breakeven approximately 2 years from today. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 66% is expected, which is extremely buoyant. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

12位美國生物技術分析師一致認爲,Iovance Biotherapeutics處於盈虧平衡的邊緣。他們預計,該公司將在2025年公佈最終虧損,然後在2026年實現1100萬美元的盈利。因此,預計從今天起大約兩年後,該公司將實現盈虧平衡。爲了達到這個盈虧平衡日期,我們計算了公司必須同比增長的速度。事實證明,預計年均增長率爲66%,非常活躍。如果事實證明這個利率過於激進,該公司的盈利時間可能比分析師預測的要晚得多。

earnings-per-share-growth
NasdaqGM:IOVA Earnings Per Share Growth May 21st 2024
納斯達克通用汽車公司:IOVA 每股收益增長 2024 年 5 月 21 日

Underlying developments driving Iovance Biotherapeutics' growth isn't the focus of this broad overview, though, bear in mind that generally a biotech has lumpy cash flows which are contingent on the product type and stage of development the company is in. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.

但是,推動Iovance Biotherapeutics增長的潛在發展並不是本次廣泛概述的重點,但請記住,生物技術公司的現金流通常不穩定,這取決於公司所處的產品類型和發展階段。這意味着,隨着公司開始從先前的投資中受益,即將到來的大幅增長率並不異常。

One thing we'd like to point out is that The company has managed its capital prudently, with debt making up 0.1% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.

我們想指出的一件事是,該公司謹慎地管理了資本,債務佔股權的0.1%。這意味着其運營資金主要來自股權資本,其低債務債務降低了投資這家虧損公司的風險。

Next Steps:

後續步驟:

This article is not intended to be a comprehensive analysis on Iovance Biotherapeutics, so if you are interested in understanding the company at a deeper level, take a look at Iovance Biotherapeutics' company page on Simply Wall St. We've also compiled a list of relevant aspects you should further examine:

本文無意對Iovance Biotherapeutics進行全面分析,因此,如果你有興趣更深入地了解該公司,請查看Iovance Biotherapeutics在Simply Wall St上的公司頁面。我們還整理了一份相關方面清單,你應該進一步研究:

  1. Valuation: What is Iovance Biotherapeutics worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Iovance Biotherapeutics is currently mispriced by the market.
  2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Iovance Biotherapeutics's board and the CEO's background.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
  1. 估值:如今,Iovance Biotherapeutics的價值是多少?價格中是否已經考慮了未來的增長潛力?我們免費研究報告中的內在價值信息圖有助於可視化Iovance Biotherapeutics目前是否被市場錯誤定價。
  2. 管理團隊:一支經驗豐富的管理團隊掌舵增強了我們對業務的信心——看看誰是Iovance Biotherapeutics董事會成員以及首席執行官的背景。
  3. 其他表現優異的股票:還有其他股票可以提供更好的前景並有良好的往績記錄嗎?在這裏瀏覽我們免費列出的這些優質股票。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論